No products in the cart.
Rabbit Polyclonal Anti-VEGFR2 antibody (STJ98952)
Supplier: St John’s Laboratory Ltd.
Recommended applications: WB, ELISA
Recommended dilution: WB 1:500-2000; ELISA 1:10000-20000
Recommended protocols: check protocols
Click or hover above images to see image description for Anti-VEGFR2 antibody.
Check alternative names for the antibodyExpand
|CD309 antibody|CD309 antigen antibody|EC 126.96.36.199 antibody|Fetal liver kinase 1 antibody|FLK-1 antibody|FLK1 antibody|FLK1, mouse, homolog of antibody|Kdr antibody|Kinase insert domain receptor (a type III receptor tyrosine kinase) antibody|Kinase insert domain receptor antibody|KRD1 antibody|Ly73 antibody|Protein tyrosine kinase receptor FLK1 antibody|Protein-tyrosine kinase receptor flk-1 antibody|soluble VEGFR2 antibody|Tyrosine kinase growth factor receptor antibody|Vascular endothelial growth factor receptor 2 antibody|VEGFR 2 antibody|VEGFR antibody|VEGFR-2 antibody|VEGFR2 antibody|VGFR2_HUMAN antibody|Anti-VEGF Receptor 2 antibody (ab2349)
SCBT cat No: sc-315|
|Catalogue No.|| |
Human, Mouse, Rat
Anti-VEGFR2 antibody detects endogenous VEGFR2.
Synthetic peptide from human protein at AA range: 1268-1341.
|Recommended dilution|| |
WB 1:500-2000; ELISA 1:10000-20000
Anti-VEGFR2 antibody was tube-contained in liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Anti-VEGFR2 antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
-20 Celsius degree. Avoid repeated freeze/thaw cycles.
|Alternative antibody names|| |
CD309 antibody, CD309 antigen antibody, EC 188.8.131.52 antibody, Fetal liver kinase 1 antibody, FLK-1 antibody, FLK1 antibody, FLK1, mouse, homolog of antibody, Kdr antibody, Kinase insert domain receptor (a type III receptor tyrosine kinase) antibody, Kinase insert domain receptor antibody, KRD1 antibody, Ly73 antibody, Protein tyrosine kinase receptor FLK1 antibody, Protein-tyrosine kinase receptor flk-1 antibody, soluble VEGFR2 antibody, Tyrosine kinase growth factor receptor antibody, Vascular endothelial growth factor receptor 2 antibody, VEGFR 2 antibody, VEGFR antibody, VEGFR-2 antibody, VEGFR2 antibody, VGFR2_HUMAN antibody
|Database links|| |
|Protein function|| |
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC. .
|Protein tissue specificity|| |
Detected in cornea (at protein level). Widely expressed. .
|Involvement in disease|| |
Hemangioma, capillary infantile (HCI) [MIM:602089]: A condition characterized by dull red, firm, dome-shaped hemangiomas, sharply demarcated from surrounding skin, usually presenting at birth or occurring within the first two or three months of life. They result from highly proliferative, localized growth of capillary endothelium and generally undergo regression and involution without scarring. . Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.; Note=Plays a major role in tumor angiogenesis. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi’s sarcoma lesions.
|Protein sequence and domain|| |
Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily. ; Contains 7 Ig-like C2-type (immunoglobulin-like) domains. ; Contains 1 protein kinase domain. The second and third Ig-like C2-type (immunoglobulin-like) domains are sufficient for VEGFC binding.
|Protein post-translational modifications|| |
N-glycosylated. .; Ubiquitinated. Tyrosine phosphorylation of the receptor promotes its poly-ubiquitination, leading to its degradation via the proteasome or lysosomal proteases. .; Autophosphorylated on tyrosine residues upon ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Phosphorylation at Tyr-951 is important for interaction with SH2D2A/TSAD and VEGFA-mediated reorganization of the actin cytoskeleton. Phosphorylation at Tyr-1175 is important for interaction with PLCG1 and SHB. Phosphorylation at Tyr-1214 is important for interaction with NCK1 and FYN. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214. .; The inhibitory disulfide bond between Cys-1024 and Cys-1045 may serve as a specific molecular switch for H(2)S-induced modification that regulates VEGFR2 function.
|Protein cellular localization|| |
Cell junction . Endoplasmic reticulum . Note=Localized with RAP1A at cell-cell junctions (By similarity). Colocalizes with ERN1 and XBP1 in the endoplasmic reticulum in endothelial cells in a vascular endothelial growth factor (VEGF)-dependent manner (PubMed:23529610). .; Isoform 1: Cell membrane; Single-pass type I membrane protein. Cytoplasm. Nucleus. Cytoplasmic vesicle. Early endosome. Note=Detected on caveolae-enriched lipid rafts at the cell surface. Is recycled from the plasma membrane to endosomes and back again. Phosphorylation triggered by VEGFA binding promotes internalization and subsequent degradation. VEGFA binding triggers internalization and translocation to the nucleus.; Isoform 2: Secreted .; Isoform 3: Secreted.
AntibodyPlus can customize Anti-VEGFR2 antibody according to your requirement, including bulk product size,etc. Please contact firstname.lastname@example.org. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.
St John’s Laboratory Ltd.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: